肥胖不孕女性生活方式干预的成本效果分析
基于LIFEstyle随机对照试验数据,从医院视角评估不孕治疗前6个月生活方式干预与直接不孕治疗的成本效果。干预组人均24个月总成本€4324,对照组€5603,成本差-€1278(P<0.05);健康活产率干预组27% vs 对照组35%,效果差-8.1%(P<0.05)。以24个月内健康活产率为终点,生活方式干预不具成本效果;延长随访或采用24个月内受孕的活产为终点时更可能具成本效果。
要点
- 以24个月内健康活产率为终点,生活方式干预不具成本效果。
- 干预组人均成本€4324低于对照组€5603,但健康活产率27%低于35%。
- 以24个月内受孕的活产为终点时,无排卵女性成本效果概率40%。
核心结论
- 不孕治疗前生活方式干预与直接不孕治疗相比,以随机化后24个月内健康活产率为终点不具成本效果。
- 采用更长随访期和活产率作为终点时,生活方式干预更可能具成本效果。
研究设计与样本
- 基于先前LIFEstyle随机对照试验数据的成本效果分析,从医院视角评估。
- 纳入BMI≥29 kg/m2(无上限)的不孕女性,干预组290例、对照组287例,分析时干预组280例、对照组284例。
- 干预为不孕治疗前6个月生活方式干预项目,对照为直接不孕治疗。
主要发现
- 随机化后24个月内人均总成本干预组€4324(SD €4276)vs 对照组€5603(SD €4632),成本差-€1278(P<0.05)。
- 健康活产率干预组27% vs 对照组35%,效果差-8.1%(P<0.05)。
- 增量成本效果比为每增加一个百分点健康活产率需€15 845。
- 每例健康活产事件平均成本干预组€15 932 vs 对照组€15 912。
- 以24个月内受孕的所有活产(不论是否在24个月内分娩)为效果终点时,生活方式干预成本效果概率在无排卵女性为40%、干预完成者为39%、≥36岁女性为29%。
临床怎么用
- 作者认为,生活方式干预的成本效果在更长随访时间和以24个月内受孕的活产为效果终点时更可能成立。
- 作者认为,该效应在无排卵女性、生活方式干预完成者和≥36岁女性中最为明显。
- 作者指出,本研究的情景分析提示在某些患者类别中提供并报销生活方式干预项目可能具成本效果,并为该领域未来研究提供方向。
局限性
- 与 study protocol 不同,未能从社会视角进行分析。
- 除LIFEstyle研究的主要结局外,使用更长随访时间观察的结局和亚组进行了探索性分析,试验对这些额外结局或亚组分析未进行效力计算。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What is the cost-effectiveness of lifestyle intervention preceding infertility treatment in obese infertile women? SUMMARY ANSWER: Lifestyle intervention preceding infertility treatment as compared to prompt infertility treatment in obese infertile women is not a cost-effective strategy in terms of healthy live birth rate within 24 months after randomization, but is more likely to be cost-effective using a longer follow-up period and live birth rate as endpoint. WHAT IS KNOWN ALREADY: In infertile couples, obesity decreases conception chances. We previously showed that lifestyle intervention prior to infertility treatment in obese infertile women did not increase the healthy singleton vaginal live birth rate at term, but increased natural conceptions, especially in anovulatory women. Cost-effectiveness analyses could provide relevant additional information to guide decisions regarding offering a lifestyle intervention to obese infertile women. STUDY DESIGN, SIZE, DURATION: The cost-effectiveness of lifestyle intervention preceding infertility treatment compared to prompt infertility treatment was evaluated based on data of a previous RCT, the LIFEstyle study. The primary outcome for effectiveness was the vaginal birth of a healthy singleton at term within 24 months after randomization (the healthy live birth rate). The economic evaluation was performed from a hospital perspective and included direct medical costs of the lifestyle intervention, infertility treatments, medication and pregnancy in the intervention and control group. In addition, we performed exploratory cost-effectiveness analyses of scenarios with additional effectiveness outcomes (overall live birth within 24 months and overall live birth conceived within 24 months) and of subgroups, i.e. of ovulatory and anovulatory women, women <36 years and ≥36 years of age and of completers of the lifestyle intervention. Bootstrap analyses were performed to assess the uncertainty surrounding cost-effectiveness. PARTICIPANTS/MATERIALS, SETTINGS, METHODS: Infertile women with a BMI of ≥29 kg/m2 (no upper limit) were allocated to a 6-month lifestyle intervention programme preceding infertility treatment (intervention group, n = 290) or to prompt infertility treatment (control group, n = 287). After excluding women who withdrew informed consent or who were lost to follow-up we included 280 women in the intervention group and 284 women in the control group in the analysis. MAIN RESULTS AND THE ROLE OF CHANCE: Total mean costs per woman in the intervention group within 24 months after randomization were €4324 (SD €4276) versus €5603 (SD €4632) in the control group (cost difference of -€1278, P < 0.05). Healthy live birth rates were 27 and 35% in the intervention group and the control group, respectively (effect difference of -8.1%, P < 0.05), resulting in an incremental cost-effectiveness ratio of €15 845 per additional percentage increase of the healthy live birth rate. Mean costs per healthy live birth event were €15 932 in the intervention group and €15 912 in the control group. Exploratory scenario analyses showed that after changing the effectiveness outcome to all live births conceived within 24 months, irrespective of delivery within or after 24 months, cost-effectiveness of the lifestyle intervention improved. Using this effectiveness outcome, the probability that lifestyle intervention preceding infertility treatment was cost-effective in anovulatory women was 40%, in completers of the lifestyle intervention 39%, and in women ≥36 years 29%. LIMITATIONS, REASONS FOR CAUTION: In contrast to the study protocol, we were not able to perform the analysis from a societal perspective. Besides the primary outcome of the LIFEstyle study, we performed exploratory analyses using outcomes observed at longer follow-up times and we evaluated subgroups of women; the trial was not powered on these additional outcomes or subgroup analyses. WIDER IMPLICATIONS OF THE FINDINGS: Cost-effectiveness of a lifestyle intervention is more likely for longer follow-up times, and with live births conceived within 24 months as the effectiveness outcome. This effect was most profound in anovulatory women, in completers of the lifestyle intervention and in women ≥36 years old. This result indicates that the follow-up period of lifestyle interventions in obese infertile women is important. The scenario analyses performed in this study suggest that offering and reimbursing lifestyle intervention programmes in certain patient categories may be cost-effective and it provides directions for future research in this field. STUDY FUNDING/COMPETING INTEREST(S): The study was supported by a grant from ZonMw, the Dutch Organization for Health Research and Development (50-50110-96-518). The department of obstetrics and gynaecology of the UMCG received an unrestricted educational grant from Ferring pharmaceuticals BV, The Netherlands. B.W.J.M. is a consultant for ObsEva, Geneva. TRIAL REGISTRATION NUMBER: The LIFEstyle RCT was registered at the Dutch trial registry (NTR 1530). http://www.trialregister.nl/trialreg/admin/rctview.asp?TC = 1530.
引用
- van Oers AM, Mutsaerts MAQ, Burggraaff JM, et al. Cost-effectiveness analysis of lifestyle intervention in obese infertile women. Hum Reprod. 2017. PMID: 28486704. doi:10.1093/humrep/dex092
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。